The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars
Drug Channels
JANUARY 10, 2023
Each exclusion list now contains about 600 products. Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira.
Let's personalize your content